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1 INTRODUCTION 
3-Hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitors, known as statins is, a class 
of drugs to lower LDL-cholesterol and the risk of 
atherosclerosis. Despite its proven long-term 
safety and efficacy by many large scale studies 
[1, 2], statins-related myotoxicity (SRM), the most 
commonly reported side effect, have been 
reported among statin users [3]. 
In light of tremendous advances in 
pharmacogenetic field in the last decade, it is 
becoming extremely difficult to ignore the 
contribution of single nucleotide polymorphism 
(SNP) in solute carrier organic transporter 1B1 
(SLCO1B1) gene had in determining statin 
response and side effects. The SLCO1B1 gene 
encodes organic anion–transporting polypeptide 
1B1 (OATP1B1), a hepatic transporter which 
mediates the uptake of statins from portal blood. 
SNPs in this gene have been shown to affect 
statin transport function and thereby have 
profound effects on statin response and side 
effects. Undeniably, a SNP in the SLCO1B1 for 
example rs4363657, which is located within 
chromosome 12, has been shown to play a 
crucial role in determining statin plasma 
concentrations and subsequent risk in developing 
myopathy [4]. The SLCO1B1 polymorphism 
markedly increased plasma-concentrations of 
active simvastatin acid and resulted in higher risk 
of simvastatin-induced myopathy [5]. Although it 
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has been recognised that elevated plasma statin 
concentration increases the risk of muscle toxicity 
[6-8], the aetiology of SRM is not well understood. 
Since many patients develop SRM such as 
muscle aches and pain, it is very important to 
determine the factors which control local skeletal 
muscle statin concentrations. In fact, little is 
known regarding the molecular determinants of 
statin distribution into skeletal muscle and its 
relevance to toxicity. 
There are several key studies that 
highlighted muscle symptoms, such as fatigue 
and cramp, may be due to lactate build-up in 
muscles. These lactate accumulations may be 
inducing dysfunctional monocarboxylate 
transporters (MCTs) possibly MCT1 and MCT4, 
two of which highly expressed lactate 
transporters in striated muscle [9, 10] and 
transcribed by SLC16A1 and SLC16A3 gene, 
respectively [10]. Other studies, has shown that 
exposure to monocarboxylate lactate, was found 
to be associated with the generation of reactive 
oxygen species (ROS) and the up-regulation of 
genes related to mitochondrial lactate oxidation 
complex in both in vitro and in vivo study using rat 
skeletal muscle cells [11, 12].  
Physiologically, the role of MCTs in skeletal 
muscle is undeniable since the organ is the major 
site of lactate production and removal in the body. 
So far, there is  no study has been carried out to 
investigate the association of the membrane 
transporter with the risk of SRM i.e., myotoxicity 
happens as a result of inhibition to the MCT 
function by a statin and subsequently increases 
muscular lactate levels for which it might be 
perceived as muscle pain or cramp. Moreover, 
substrates for MCTs have not been limited to 
endogenous metabolites but also xenobiotics 
such as statins, gamma-hydroxybutyrate and 
valproic acid [13-16] which thus suggest their 
potential role in predicting SRM.  
Our group has previously shown that HK-2 
cells (a proximal tubule cell line originated from 
human kidney) express MCT1 at both mRNA and 
functional levels [17]. A number of studies also 
have characterised MCT functions in L6 skeletal 
muscle cells [12, 18, 19], by which MCT1 in 
particular mediated lactate transport in both 
mitochondrial and sarcolemma membrane of a 
striated muscle fibre. However, limited evidence 
is available to explain how statins affect the 
function of MCT1 in muscle cells.  There are 
evidences indicating that MCT4, but not MCT1, 
being the statin target and upregulated during 
statin-induced cytotoxicity [20, 21]. In terms of 
blood lactate transport and removal, MCT1 and 
MCT4 were both considered important mediators 
for blood lactate removal [22, 23] thus implicating 
their vital role in maintaining muscle lactate 
concentration. Therefore in this study, we 
determined whether SRM could be promoted by 
the inhibition of MCT1 function by statins primarily 
looking at their ability to inhibit lactate uptake into 
the L6 cells. It is possible that the inhibition of 
MCT1 by statins could advocate myotoxicity due 
to affected lactate transport.  
Apart from the above mentioned SLC 
transcribing membrane transporters, the interplay 
role by efflux transporters typically ATP-binding 
cassette (ABC), in muscle such as multi-drug 
resistance associated protein (MRPs), may also 
modulate statin local exposure in muscle and 
eventually intensify muscle toxicity in the event of 
function inhibition of the transporters. Moreover, 
our group had also shown that 5-(3-92-(7-
chloroquinolon-2-yl)ethenyl)phenyl)-8-
dimethylcarbamyl-4,6-dithiaoctanoic acid 
(MK571) could be used as a high affinity MRP 
inhibitor in an MRP-mediated CMFDA efflux 
assay using HK-2 cells [17]. This dual dye assay 
was developed to evaluate the impact of two 
inhibitors, MK571 (MRP inhibitor) and CSA 
(MDR1 inhibitor); whereby the accumulation of 
dye provides an indirect measure of efflux 
inhibition of the ABC transporters. Therefore, the 
aim of the second part of this study was to 
evaluate the impact of statins on functional 
expression of efflux transporters. In order to 
assess the relative affinity of different statins to 
the MRPs function, the magnitude of the dye 
efflux inhibition was compared to MK571. 
2 MATERIALS AND METHODS 
2.1 Materials and reagents 
Number RT2 ProfilerTM Rat Drug Transporter PCR 
array (Catalogue no:  PARN-070Z) and reagents 
were purchased from Qiagen Ltd (Crawley, UK). 
Simvastatin, atorvastatin, pravastatin, and 
rosuvastatin were gifts from AstraZeneca 
(Alderley Park, Cheshire, UK). [2-3H]-DL-lactate 
(at activity of 20 Ci/mmol) was purchased from 
Hartmann Analytic (Braunschweig, Germany). SV 
Total RNA Isolation System was purchased from 
Promega (Southampton, UK). SYBR Green Dye 
Master Mix for real-time polymerase chain 
reaction was purchased from Roche Applied 
Sciences (Burgess Hill, UK). Reagents for dye 
assay; 5-chloromethylfluorescein diacetate 
(CMFDA) was purchased from Invitrogen 
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(Paisley, UK). Unless otherwise stated, all other 
reagents including phloretin (well-defined MCT1 
inhibitor) and α-cyano-4-hydroxycinnamate, CHC 
(a typical MCT1, 2 and 4 inhibitors) were 
purchased from Sigma-Aldrich (Dorset, UK). 
 
2.2 L6 rat muscle cell line 
The L6 rat muscle cell line (ATCC® number: CRL-
1458TM), supplied at myoblast stage, was kindly 
provided by Dr Audrey Brown of Newcastle 
University. L6 exists as myoblasts when cultured 
in maintenance culture medium, which comprises 
high glucose DMEM supplemented with 10 % 
foetal calf serum, 200 units/ml penicillin and 200 
µg/ml streptomycin, until 70-80 % confluency. 
The cells were then introduced to differentiation 
medium (high glucose DMEM supplemented with 
2 % horse serum, 200 units/ml penicillin and 200 
µg/ml streptomycin), upon which the cells 
differentiate into myotube until approximately 80 
to 90 % confluent. L6 cells used in this study 
were within passage numbers 11 through 30. 
For the uptake and efflux experiments, L6 
cells were seeded at 50,000 cells/well and 20,000 
cells/well onto 24-well plates and 96-well plates 
(Coster, Corning Incorporated Corning, UK), 
respectively, for 2 days or until the indicated 
confluence. Cells were then differentiated into 
myotube formation by incubating them with 
differentiation media. The cell monolayers were 
fed a fresh differentiation media every 2 days and 
were used for uptake experiments on day 7.  
 
2.3 Isolation of total RNA and qPCR array for rat 
membrane transporters 
On day 7 of differentiation, total RNA was isolated 
from L6 cells at myotube stage to determine the 
expression of a series of uptake (both SLC and 
SLCO sub-groups) and efflux (ABC group) 
transporters by qPCR array plate. In order to 
assess whether statins affect gene expression of 
the uptake transporters in L6 myotubes, the cells 
were pre-treated on day 5 with simvastatin (2 µM) 
for 48 hrs prior to RNA extraction and compared 
with untreated control cells (contained 0.02 % 
methanol only). The protocols for RNA extraction 
and qPCR array were carried out as previously 
described [17]. 
 
 2.4 Functional assay of monocarboxylate 
transporters (MCTs)  
2.4.1 3H-DL-lactate uptake assay 
Lactate uptake experiments by L6 cells seeded 
on 24-well plates in the presence of statins were 
carried out according to the previously described 
protocols [17]. 
 
2.4.2 3H-DL-lactate efflux assay 
The efflux of radiolabelled substrate was used to 
functionally measure the expression of MCT. 
Briefly, cells were pre-incubated with 300 µl of 
Krebs containing radiolabelled DL-lactate (50 µM) 
for 60-90 minutes at pH 6.0, 37 °C to ensure cells 
were loaded with radiolabelled substrate. After 
incubation, cells were then washed with ice-cold 
Krebs at pH 7.4 three times. To initiate lactate 
efflux, cell monolayers were incubated with 300 µl 
pre-warmed 3H-DL-lactate-free Krebs buffer at pH 
6.0 with and without 500 µM inhibitor. After 
several time intervals, the cell monolayers were 
solubilised in 0.5 mL of 0.05 % SDS and 
transferred to scintillation vials.  
The radioactivity was measured as 
described earlier [17]. Fractional efflux rate (% of 
radiolabelled lactate efflux every 2 min intervals) 
was calculated according to (1) and the 
magnitude of MCT-mediated 3H-DL-Lactate efflux 
in Krebs-inhibitor solution was compared to that 
of control with Krebs buffer only (refer 
Supplementary document for an example of 
calculation). 
 
 
  (1) 
 
2.5 Functional assay of Mrp efflux transporters 
The L6 cells were seeded at a density 20,000 
cells/well and cultured for 24 hours before 
induction of differentiation into myotube formation 
for 6 or 7 days. Retention of MRP-mediated 
fluorescent product of CMFDA (i.e. glutathione 
methylfluorescein, GSMF) was used to determine 
MRPs function in L6 cells and has been 
previously described [17].  
 
2.6 Statistical analysis 
All statistical analysis on data was performed 
using GraphPad Prism software version 4 
(GraphPad Software Inc. San Diego, CA, USA). 
For kinetic analysis, the Michaelis-Menten 
constant (Km) and maximum velocity of substrate 
binding (Vmax) of DL-lactate uptake were analysed 
from a fitted nonlinear regression analysis. 
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Statistical difference between group means was 
tested using Student’s unpaired t-test (also 
known as independent- samples t-test) or a One-
Way ANOVA with Dunnett’s post-hoc test as 
appropriate. Paired t-test was used when the 
mean of continuous variables between groups 
were related in some way. A value of p< 0.05 was 
considered statistically significant. Unless 
otherwise stated, results are expressed as the 
mean ± SEM from at least three separate 
experiments performed on separate days.  
3 RESULTS 
3.1 Relative mRNA expression of key uptake 
and efflux transporters in L6 myotubes  
Among the SLC and SLCO genes transcribing 
uptake transporters, mRNA for Mct1 (transcribed 
by Slc16a1), Mct8 (Slc16a2) and Oatp3a1 
(Slco3a1) were found to be highly expressed in 
L6 cells in contrast to Mct4 (Slc16a3) expression 
(Figure 1A). 
 
Figure. 1 A selection of key (A) uptake and (B) efflux 
transporters in cDNA of L6 myotubes analysed by drug 
transporters qPCR array. The relative expression level was 
analysed by standard qPCR Array and data analysis from 
SABiosciences website 
(http://www.sabiosciences.com/pcrarraydataanalysis.php) and 
calculated using the 2−ΔΔCp method and are relative to the 
geometric mean of five housekeeping genes provided by the 
array. Error bars represent the mean ± SEM (n=3). 
 
 Among ABC efflux transporters, mRNA of Mrp1 
(Abcc1) was expressed at highest level compared 
to Mrp2 (Abcc2), Mrp3 (Abcc3), Mrp4 (Abcc4), 
Mrp5 (Abcc5) and Mrp6 (Abcc6). The mRNA 
expression of other efflux transporters such as 
Bcrp1 (Abcg2) and Mdr1 (Abcb1) were also 
expressed at low level (Figure 1B). Among the 
highly mRNA-expressed uptake (i.e., Mct1 and 
Oatp3a1) and efflux (i.e., Mrp1) transporters in 
the L6 myotubes, pre-treatment with simvastatin 
(2 µM for 48 hours) did not significantly reduce 
the level of expression in compared to the control. 
 
 
3.2 The expression of MCT1 function in L6 cells 
The uptake of 3H-DL-lactate (50 µM) was used to 
assess MCT function in L6 cells. The time course 
for lactate uptake into L6 cells at pH 6.0 (at 37°C) 
is shown in Figure 2A. The 3H-DL-lactate uptake 
was linear up to 5 minutes. Therefore a 2 minutes 
incubation time was chosen for subsequent 
uptake experiments. The effect of extracellular pH 
and sodium ion concentration on 3H-DL-lactate 
uptake was examined over the pH range of 5.5 to 
7.4. 3H-DL-lactate uptake was significantly higher 
(p<0.001) at lower extracellular pH (pH 5.5 vs pH 
7.4) in the presence and absence of Na+. The 
uptake at pH 5.5 was found not to be affected by 
Na+ concentration (Figure 2B). The uptake 
experiments were subsequently performed at pH 
6.0 in the presence of Na+ to mimic physiological 
conditions.  
 
 
Figure. 2  Time course and pH-dependency uptake of 3H-
DL-Lactate in myotubes of L6 rat muscle cells. (A) The 3H-DL-
Lactic acid (50 μM) uptake by L6 (at pH 6.0 and 37°C) was 
linear up to 5 minutes and 2 minutes incubation time was 
chosen for subsequent experiments. (B) Effect of pH and Na+ 
on the uptake of DL-lactate (50 μM) by L6 cells. Data are 
presented as mean ± SEM (n= 12) from three independent 
determinations. *** p< 0.001; Na+, sodium ion. 
 
The kinetics of 3H-DL-lactate uptake by the L6 
cells is shown in Figure 3A and Figure 3B. The 
uptake of DL-lactate (1 µCi/mL) was shown to be 
concentration-dependent (0.1 mM to 20 mM). A 
nonlinear regression analysis with a simple 
 
 
 
J. of Biomed. & Clin. Sci. 2016, Vol 1 (1), 17-26  Original Article 
 
http://apps.amdi.usm.my/journal/       21 
 
Michaelis-Menten equation gave a Km value of 
16.17 ± 2.4 mM (95% CI = 11.47- 20.87) in the 
presence of Na+ and the Km value of 15.63 ± 3.0 
mM (95% CI= 9.75 – 21.51) in the absence of 
Na+.  The Km values in both conditions were 
found not to be significantly different from each 
other (Figure 3C) suggesting that the presence of 
Na+ has no impact upon the kinetics of the 
transporter in the cells. 
 
 
 
Figure. 3  Concentration-dependence of DL-lactate 
uptake by L6 myotubes. 3H-DL-Lactate uptake at 0.1 – 20 mM 
final concentration (at pH 6.0 and 37 °C) was determined over 
2 minutes in (A) the presence of extracellular Na+ and (B) the 
absence of extracellular Na+. The Km values were 16.17 ± 2.4 
mM (95% CI: 11.47 - 20.87) and 15.63 ± 3.0 mM (95% CI: 
9.75 – 21.51) in the presence and absence of Na+, 
respectively. Data are presented as mean ± SEM from three 
independent determinations. (C) The mean Km value in the 
presence of Na+ (16.17 ± 2.4 mM) was not significantly 
different (paired t-test) compared to that without Na+ (15.63 ± 
3.0 mM). Data are presented as mean ± SEM (n = 6) from six 
parallel determinations. Na+, sodium ion. 
 
3.3 The impact of statin on the MCT-mediated 
3H-labelled DL-lactate uptake 
Inhibition assay was performed to determine 
whether statins affect functional expression of 
Mct1 in particular. L6 cells were incubated with 
3H-DL-lactate in the absence and the presence of 
statins (i.e. simvastatin, atorvastatin, pravastatin 
and rosuvastatin). To confirm that statin was a 
substrate for Mct1, the magnitude inhibition of 
DL-lactate uptake by all tested statins were 
compared to phloretin (a well-defined Mct1 
inhibitor) and CHC (a typical Mct1, 2 and 4 
inhibitors). Figure 4 summarises the degree of 
DL-lactate uptake inhibition. Simvastatin and 
atorvastatin significantly (p<0.001) inhibited DL-
lactate uptake to the same degree as phloretin 
and CHC with IC50 values of 10.7 ± 1.2 µM and 
7.4 ± 0.9 µM, respectively (Table 1). In contrast, 
the inhibitory effects of pravastatin and 
rosuvastatin were not significant even up to 1 
mM.  
 
Figure. 4  The DL-lactate uptake (50 μM) in the presence 
of statins, CHC and phloretin (all at 1 mM). Data are mean 
±S.E.M. n = 12, each data point was derived from a triplicate 
of experiments and from four independent determinations. 
Data were analysed using One-Way ANOVA with Dunnett’s 
post-test and compared to that of control without the presence 
of inhibitor. CHC, α-Cyano-4 hydroxycinnamic acid N-ethyl-
N,N-diisopropylammonium salt;*** p< 0.001; ns, non-
significant. 
 
 
 
The fractional efflux rate of 3H-DL-Lactate (50 
µM) at each time interval was low and the values 
were consistently at the level below than 10% 
from the baseline reading (Figure 5). 
Furthermore, the fractional efflux rates for DL-
lactate were similar when co-incubated with Mct1 
inhibitors, phloretin (a typical MCT1 inhibitor), 
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CHC (non-specific MCT inhibitor), simvastatin (a 
representative of lipophilic statin) and pravastatin 
(a representative of hydrophilic statin), at a 
concentration of 500 µM of each inhibitor to that 
of control (substrate only).  In contrast to the 
uptake function of Mct1 (section 3.2), this finding 
suggests that Mct1 in the L6 muscle cells does 
not exhibit efflux function for DL-lactate.   
 
 
 
Figure. 5  Efflux assay for determination of MCT1-
mediated 3H-DL-Lactate (50 μM) efflux in L6 cells. There was 
no significant inhibition of DL-lactate (50 μM) efflux. Efflux 
rates were approximately 10 % for all conditions. All inhibitors 
were at 500 μM and each point represented as mean ±SEM 
(n =9) from three independent experiments. MCT, 
monocarboxylate transporter; CHC, α-Cyano-4 
hydroxycinnamic acid N-ethyl-N,N-diisopropylammonium salt. 
 
3.4 The impact of statins on the MRP-mediated 
CMFDA efflux 
Our group previously published that MK571 could 
be used a specific inhibitor of MRP-mediated 
GSMF (a fluorescent component of CMFDA), as 
an assay to functionally characterised the 
functional expression of MRP transporter using 
HK-2 cell line. Consistent with the previous 
findings in the HK-2 cells, GSMF retention was 
significantly higher when L6 cells were treated 
with MK571 compared to that of untreated control 
with CMFDA dye only (Figure 6A) (p < 0.0001). 
Pre-treatment of L6 myotubes with (Figure 6B1) 
and without (Figure 6B2) simvastatin (2 µM for 
48 hours) did not result in different MK571 IC50 
values (0.90 ± 0.2 µM vs 1.03 ± 0.2 µM) which 
thus suggested that simvastatin did not modify 
Mrp function in the cells.   
 
 
 
Figure. 6  Inhibition of MRP-mediated CMFDA efflux by 
MK571 in L6 cells. (A) Addition of MK571 at 5 μM resulted in a 
significant increase in CMFDA dye retentioncompared to that 
of control wells with Km value of 6.66 ± 3.6 μM. ***P<0.0001 
demonstrates the level of significance compared to the control 
without MK571 pre-treatment (paired T-test). (B) Dose-
response curve for MRP-mediated CMFDA (1 μM) efflux 
inhibition by MK571 in L6 cells. L6 myotubes were exposed 
with simvastatin (B1) and without simvastatin (B2) pre-
treatment for 48 hrs and resulted in MK571 IC50 values of 
0.90 ± 0.2 µM and 1.03 ± 0.2 µM, respectively. Dye retention 
was measured after treatment with a range of MK571 
concentrations after 40 minutes. Each point represents mean 
+ SEM (n = 18) from 3 independent experiments.  
 
 
Among four statins used in this experiment, only 
simvastatin was significantly inhibited (p<0.05) 
MRP-mediated GSMF efflux, however the 
magnitude of the inhibition was more than five-
fold lower to that seen with MK571 (Figure 7). 
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Figure. 7    The inhibition by statins of the MRP-mediated 
CMFDA dye efflux in L6 cells. The concentration of all 
inhibitors used were 10 μM. Data are presented as mean ± 
SD (n=18) from 3 independent experiments. Data were 
analyzed using one-way ANOVA and Dunnett’s post-hoc 
test;***P<0.0001, *P<0.05 and ns (non-significant) versus 
control. 
4 DISCUSSION 
We have, previously, shown both mRNA and 
functional expression of monocarboxylate 
transporter 1 (MCT1) in HK-2 cells, using DL-
lactate as substrate [17]. In the study, the high 
MCT-expressed HK-2 cells were found to be 
transported by mechanism obeying Michaelis-
Menten kinetics (Km). The DL-lactate uptake was 
likely mediated through the MCT1 transporter 
although the Na+ dependence uptake may have 
suggested the involvement of SMCT1 (sodium-
coupled MCT1), but this was not confirmed 
further [17].  
We then extended the functional study of 
MCT using a model of rat skeletal muscle i.e. L6 
cells, since the statin related side effects 
commonly seen in muscle. In the present study, 
the Km value for the DL-lactate uptake in the L6 
cells was higher compared to that seen in the 
previously studied HK-2 cells. Relatively, the 
mRNA expression level for MCT1 in the HK-2 
cells was higher than L6 rat skeletal cells, 
suggesting its lower affinity to DL-Lactate in the 
muscle model. Likewise, it could be possible that 
HK-2 cells extensively transport or eliminate 
lactate as metabolite substrate and/or product of 
the endogenous production, thus resulting in 
lower Km values (high driving forces) than that of 
muscle cells, since HK-2 cells were found to 
express more MCTs; MCT1, MCT2 and MCT4, at 
both mRNA and protein levels [24]. 
In contrast to the findings in HK-2 cells 
[17], we found that the DL-lactate uptake in L6 
cells was Na+-independent. Since the absence of 
SMCT1 in the HK-2 cells was verified by qPCR, it 
was suggested that the inhibition of Na+/H+ 
exchange in the HK-2 cells resulted in higher 
lactate uptake in the presence of Na+ [17]. 
Therefore, one possible explanation of this 
discrepancy could be the result of high regulation 
of lactate/H+ exchange since it was found as 
major pH regulator in muscle cell compared to 
other mechanisms such as Na+/H+ exchange and 
bicarbonate/H+ [25]. It seems that only the 
presence of excess proton (H+) intensifies the 
lactate transport, in accordance with other 
previous findings [10, 26] and thus suggests that 
muscle symptoms among lipophilic statin users in 
particular, is associated with the disturbance of 
pH regulation in muscle and eventually lactic 
acidosis which might lead to apoptosis and 
toxicity. 
Lipophilic statins, simvastatin and 
atorvastatin, have a significant impact on MCTs, 
presumably MCT1 since this particular membrane 
transporter is found to be present in almost all 
tissues including skeletal muscles, with specific 
location within the tissues [10]. MCT1 is also 
localized in sarcolemmal membrane of 
mitochondrion [27-29], therefore, it is possible 
that statins cause muscle toxicity by interfering 
with mitochondrial function. Indeed this has been 
demonstrated by both in vitro and in vivo 
regarding the mode of action of simvastatin [30-
32], suggesting that lipophilic statins are better at 
targeting MCT1 to induce mitochondrial toxicity 
than hydrophilic statins. Further work in patient 
cohort is thus needed to determine whether 
altered function of MCT1 due to genetic mutation 
would exacerbate statin myotoxicity and/or 
mitochondrial toxicity. 
In contrast to the effect on MCTs, lipophilic 
statins did not inhibit cellular MRP efflux 
transporters. The functional expression of efflux 
transporter in this study is likely to have been 
attributed to by Mrp1 owing to its relatively high 
expression level in the L6 myotubes. MRP1 is 
expressed ubiquitously, and is localised to the 
basolateral, rather than apical, membrane of 
epithelial cells. As with MRP2, MRP1 primarily 
effluxes a wide range of substrates [33, 34], and 
may acts as the most important efflux transporter 
for the extrusion of toxins or metabolites from 
cellular metabolism as suggested by Mueller and 
colleagues [35]. Among MRPs, although less 
evidence is available on the capacity of MRP1 for 
statin efflux than that demonstrated by MRP2 
 
 
 
J. of Biomed. & Clin. Sci. 2016, Vol 1 (1), 17-26  Original Article 
 
http://apps.amdi.usm.my/journal/       24 
 
[36], it has been demonstrated that polymorphism 
in both ABCC1 (MRP1) and ABCC2 (MRP2) 
genes are equally involved in the incidence of 
statin resistance and response i.e. patients fail to 
achieve adequate reduction of LDL-C level [37, 
38]. Since MRP2, the 190 kDa membrane 
glycoprotein, is highly expressed in human apical 
hepatocytes [39, 40], the mutation and/or 
inhibition of MRP2 may become a major 
determinant of biliary excretion of statins resulting 
in statin plasma elevation, a risk factor for statin-
related myotoxicity. Nevertheless, at local 
exposure in skeletal muscle cells, it has been 
shown that both atorvastatin and rosuvastatin 
accumulation is reduced due to MRP1 over-
expression [41] suggesting that the efflux of both 
statins is also attributed to the MRP1 transporter 
which is consistent with that found by Dorajoo et 
al. in 2008 [42]. 
5 CONCLUSION 
We were able to demonstrate that simvastatin 
had higher affinity to MRPs than MCT1 and other 
statins, based upon the inhibition of MRP-
mediated CMFDA efflux in the L6 cells. This 
observation warrants further evaluations possibly 
by direct transport study using radiolabelled 
simvastatin possibly in skeletal mitochondrion 
model. 
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Supplementary document 
 
Calculation of fractional 3H-DL-lactate efflux  
 
 
 Reading 1 
 
Reading 2         Reading 
3 
Radioactivity collected on the 1st 2 min  4381 4032 3945 
Radioactivity collected on the 2nd 2 min  1493 1390 1529 
Radioactivity collected on the 3rd 2 min  567 587 506 
Radioactivity collected on the 4th 2 min  348 316 366 
Radioactivity collected on the 5th2 min  229 233 245 
Radioactivity collected on the 6th 2 min  231 238 236 
Radioactivity collected on the 7th 2 min  195 197 197 
Radioactivity collected on the 8th 2 min  140 137 138 
Final radioactivity remained in cells  2846 2821 2804 
Total radioactivity  10430 9951 9966 
 
    
     
Thus, fractional efflux rate (%) was gained as follow; 
 
 Reading 1  Reading 2  Reading 3  MEAN  
1  42.00384  40.51854  39.58459  40.70232  
2  24.68177  23.4837  25.39445  24.51997  
3  12.44513  12.96092  11.26447  12.22351  
4  8.723991  8.016235  9.182137  8.640788  
5  6.289481  6.425814  6.767956  6.494417  
6  6.770223  7.014441  6.992593  6.925752  
7  6.130148  6.244057  6.275884  6.216696  
8  4.688547  4.631508  4.690687  4.670247  
 
An example for the values in Reading 1 from the table above were derived as follow; 
 
 
 
42.00384 = 4381/10430*100 
24.68177 = (1493/ (10430-4381)*100 
12.44513 = (567/ (10430-(1493+4381))*100 
8.723991 = (348/ (10430 – (4381+1493+567)*100 
6.289481 = (229/ (10430 – (4381+1493+567+348))*100 
6.770223 = (231/ (10430 – (4381+1493+567+348+229))*100 
6.130148 = (195/ (10430 – (4381+1493+567+348+229+231))*100 
4.688547 = (140/(10430 – (4381+1493+567+348+229+231+195))*100 
 
